Constrictive bronchiolitis obliterans: The fibrotic airway disorder

Expert Review of Respiratory Medicine

Volumn 1, Issue 1, 2007, Pages 139-147

  Epler, Gary R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BOOP; bronchiolar airway disease; bronchiolitis obliterans; bronchiolitis obliterans organizing pneumonia; constrictive bronchiolitis; small airways disease

Indexed keywords

EID: 77955081510     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.1.139     Document Type: Article

References (61)

1. Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am. J. Respir. Crit. Care Med. 168, 1277–1292 (2003).
2. Couture C, Colby TV. Histopathology of bronchiolar disorders. Semin. Respir. Crit. Care Med. 24 (5), 489–497 (2003).
3. Epler GR, Colby TC. Bronchiolitis obliterans and other bronchiolar airway disorders. In: Bone’s Atlas of Pulmonary Care Medicine. 3rd Edition. Crapo JD (Ed.). Current Medicine, PA, USA, Chapter 5, 69–79 (2005).
4. Popper HH. Bronchiolitis, an update. Virchows Arch. 437, 471–481 (2000).
5. Homma S, Sakamoto S, Kawabata M et al. Comparative clinicopathology of obliterative bronchiolitis and diffuse panbronchiolitis. Respiration 73, 481–487 (2006).
6. Visscher DW, Myers JL. Bronchiolitis. The pathologist’s perspective. Proc. Am. Thorac. Soc. 3, 41–47 (2006).
7. King TE. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced and idiopathic. Semin. Respir. Crit. Care Med. 24 (5), 567–576 (2003).
8. Thomason JWW, Rice TW, Milstone AP. Bronchiolitis obliterans in a survivor of a chemical weapons attack. JAMA 290 (5), 598–599 (2003).
9. Ghanei M, Mokhtar M, Mohammad MM, Aslani J. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur. J. Radiol. 52, 164–169 (2004).
10. Ghanei M, Panahi Y, Mojtahedzadeh M, Khalili AH, Aslani J. Effect of γ interferon on lung function of mustard gas exposed patients, after 15 years. Pul. Pharm. Therap. 19, 148–153 (2006).
11. Kreiss K, Gomaa A, Kullman G, Fedan K, Simoes EJ, Enright PL. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N. Engl. J. Med. 347 (5), 330–338 (2002).
12. Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K. Bronchiolitis obliterans syndrome in popcorn production plant workers. Eur. Respir. J. 24, 298–302 (2004).
13. Mann JM, Sha KK, Kline G, Breuer FU, Miller A. World Trade Center dyspnea: bronchiolitis obliterans with functional improvement. Am. J. Ind. Med. 48, 225–229 (2005).
14. Yang CF, Wu MT, Chiang AA et al. Correlation of high-resolution CT and pulmonary function in bronchiolitis obliterans: a study based on 24 patients associated with consumption of Sauropus androgynus. AJR Am. J. Roentgenol. 168 (4), 1045–1050 (1997).
15. Hsiue TR, Guo YL, Chen KW, Chen CW, Lee CH, Chang HY. Dose–response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus. Chest 113 (1), 71–76 (1998).
16. Oonakahara K, Matsuyama W, Higashimoto I et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Japan. Respiration 72, 221 (2005).
17. Marras TK, Chan CKN. Obliterative bronchiolitis complication bone marrow transplantation. Semin. Respir. Crit. Care Med. 24 (5), 531–541 (2003).
18. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin. Chest Med. 25 (1), 189–201 (2004).
19. Khalid M, Al Saghir A, Saleemi S et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur. Respir. J. 25, 490–493 (2005).
20. Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann. Thorac. Surg. 79, 1051–1052 (2005).
21. Tomas LHS, Loberiza FR, Klein JP et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 128, 153–161 (2005).
22. Huisman C, van der Straaten HM, Canninga-van Dijk MR, Fijnheer R, Verdonck LF. Pulmonary complications after T-cell depleted allogeneic stem cell transplantation: low incidence and strong association with acute graft-versus-host disease. Bone Marrow Transplant. 38, 561–566 (2006).
23. Bryant DH. Obliterative bronchiolitis in haematopoietic stem cell transplantation: can it be treated? (Editorial). Eur. Respir. J. 25, 402–404 (2005).
24. Soubani AO, Uberti JP. Bronchiolitis obliterans follwoing haematopoietic stem cell transplantation. Eur. Respir. J. 29, 1007–1019 (2007).
25. White ES, Tazelaar HD, Lynch JP. Bronchiolar complications of connective tissue diseases. Semin. Respir. Crit. Care Med. 24 (5), 547–565 (2003).
26. Camus P, Colby TV. The lung in inflammatory bowel disease. Eur. Respir. J. 15, 5–10 (2000).
27. Shah AP, Xu H, Sime PJ, Trawick DR. Severe airflow obstruction and eosinophilic lung disease after Stevens–Johnson syndrome. Eur. Respir. J. 28 (6), 1276–1279 (2006).
28. Brown MJ, English J, Müller NL. Bronchiolitis obliterans due to neuroendocrine hyperplasia. AJR Am. J. Roentgenol. 168, 1561–1562 (1997).
29. Ge Y, Eltorky MA, Ernst RD, Castro CY. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Ann. Diagn. Pathol. 11 (2), 122–126 (2007).
30. Miller RR, Muller NL. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am. J. Surg. Pathol. 19 (6), 653–658 (1995).
31. Davies SJ, Gosney JR, Hansell DM et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognized spectrum of disease. Thorax 62 (3), 248–252 (2007).
32. Fujimoto W, Kanehiro A, Kuwamoto-Hara K et al. Paraneoplastic pemphigus associated with Castleman’s disease and asymptomatic bronchiolitis obliterans. Eur. J. Dermatol. 12 (4), 355–359 (2002).
33. Radzikowska E, Pawlowski J, Chabowski M, Langfort R. Constrictive bronchiolitis obliterans in patient with Castelman’s disease. Monaldi Arch. Chest Dis. 63 (4), 226–229 (2005).
34. Elliott CG, Colby TV, Kelly TM, Hicks HG. Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 96 (3), 672–674 (1989).
35. Rinaldi M, Martinelli L, Volpato G et al. Gastro-esophageal reflux as cause of obliterative bronchiolitis: a case report. Transplant. Proc. 27 (3), 2006–2007 (1995).
36. Miyagawa-Hayashino A, Wain JC, Mark EJ. Lung transplantation biopsy specimens with bronchiolitis obliterans or bronchiolitis obliterans organizing pneumonia due to aspiration. Arch. Pathol. Lab. Med. 129, 223–226 (2005).
37. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med. 166 (4), 440–444 (2002).
38. Scott AIR, Sharples LD, Stewart S. Bronchiolitis obliterans syndrome. Risk factors and therapeutic strategies. Drugs 65 (6), 761–771 (2005).
39. Smith PW, Wang H, Parini V et al. Lung transplantation in patients 60 years and older: results, complications, and outcomes. Ann. Thorac. Surg. 82 (5), 1835–1841 (2006).
40. Martinu T, Howell DN, Davis D, Steele MP, Palmer SM. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 129, 1016–1023 (2006).
41. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant. 21 (3), 297–310 (2002).
42. Lama VN, Murray S, Mumford JA et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am. J. Respir. Crit. Care Med. 172, 379–383 (2005).
43. Moffatt-Bruce SD, Karamichalis J, Robbins RC, Whyte RI, Theodore J, Reitz BA. Are heart–lung transplant recipients protected from developing bronchiolitis obliterans syndrome? Ann. Thorac. Surg. 81, 286–291 (2006).
44. Burton CM, Iversen M, Milman N et al. Outcome of lung transplanted patients with primary graft dysfunction. Eur. J. Cardiothorac. Surg. 31 (1), 75–82 (2007).
45. Daud SA, Yusen RD, Meyers B et al. The impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 175 (5), 507–513 (2007).
46. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on primary lung graft dysfunction Part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 24, 1454–1459 (2005).
47. Dupont LJ, Dewandeleer Y, Vanaudenaerde BM, Van Raemdonck DE, Verleden GM. The pH of exhaled breath condensate of patients with allograft rejection after lung transplantation. Am. J. Transplant. 6, 1486–1492 (2006).
48. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc. Am. Thorac. Soc. 3, 444–449 (2006).
49. Luckraz H, Goddard M, McNeil K, Atkinson C, Sharples LD, Wallwork J. Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways? Ann. Thorac. Surg. 82, 1212–1218 (2006).
50. Epler GR. Panbronchiolitis. Encyclopedia of Respiratory Medicine. Laurent GJ, Shapiro SD (Eds). Elsevier Ltd, London, UK, 297–300 (2006).
51. Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest 128, 3611–3617 (2005).
52. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant. 24 (9), 1440–1443 (2005).
53. Yates B, Murphy DM, Forrest IA et al. Azithromycin reverse airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 172, 772–775 (2005).
54. Williams TJ, Verleden GM. Azithromycin: a plea for mulitcenter randomized studies in lung transplantation. Am. J. Respir. Crit. Care Med. 172, 657–659 (2005).
55. Vanaudenaerde BM, Wuyts WA, Geudens N et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am. J. Transplant. 7, 76–82 (2007).
56. Laporta Hernández R, Ussetti Gil P, García Gallo C, de Pablo Gafas A, Carreño Hernádez MC, Ferreiro Álvarez MJ. Rapamycin in lung transplantation. Transplant. Proc. 37 (9) 3999–4000 (2005).
57. Dosanjh A. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur. J. Pharm. 536, 219–222 (2006).
58. Angel L, Homma A, Levine SM. Bronchiolitis obliterans. Semin. Respir. Crit. Care Med. 21 (2) 123–134 (2000).
59. Berstad AE, Aaløkken TM, Kolbenstvedt A, Bjørtuft Ø. Performance of long-term CT monitoring in diagnosing bronchiolitis obliterans after lung transplantation. Eur. J. Radiol. 58, 124–131 (2006).
60. de Jong PA, Dodd JD, Coxson HO et al. Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning. Thorax 61, 799–804 (2006).
61. Markopoulou KD, Cool CD, Elliot TL et al. Obliterative bronchiolitis: varying presentations and clinicopathological correlation. Eur. Respir. J. 19, 20–30 (2002).